Paulex Bio Announces Registration of Phase 1/2a Trial of PAL-119, an Oral Small Molecule Designed to Regenerate and Restore the Function of Insulin-Producing Beta Cells
First-in-human study plans to enroll healthy volunteers and adults with Type 1 or Type 2 diabetes to evaluate PAL-119's safety and tolerability and explore its effects on the body's own insulin production SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Paulex Bio Inc., a biopharmaceutical company...
Covered in this story
Call it yourself
No calls on $PAL yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Proficient Auto Logistics Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.